185346-79-6

Usage

Uses

Used in Pharmaceutical Research:
4-(Benzyloxy)-1-bromo-2-fluorobenzene is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structural features allow for the creation of novel drug candidates with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(Benzyloxy)-1-bromo-2-fluorobenzene serves as a versatile building block for the preparation of a wide range of organic molecules. Its presence of a bromine and fluorine atom, along with the benzyloxy group, enables various synthetic transformations, facilitating the synthesis of complex organic molecules with diverse functional groups.
Used in Medicinal Chemistry:
4-(Benzyloxy)-1-bromo-2-fluorobenzene is utilized as a starting material in the design and synthesis of new bioactive molecules for medicinal chemistry research. Its unique structural elements can be further modified to explore novel chemical space and identify potential drug candidates with improved pharmacological properties.
Used in Chemical Libraries:
4-(Benzyloxy)-1-bromo-2-fluorobenzene can be incorporated into chemical libraries for high-throughput screening in drug discovery. Its unique structural features can contribute to the diversity of the library, increasing the chances of identifying new lead compounds with potential therapeutic applications.

Upstream product

• 100-39-0 benzyl bromide 
• 121219-03-2 4-bromo-3-fluorophenol 
• 100-44-7 benzyl chloride 
• 348-57-2 2,4-difluorobromobenzene 
• 100-51-6 benzyl alcohol 
• 72216-35-4 3-fluorophenyl phenylmethyl ether 
• 372-20-3 3-fluorophenol 

Downstream Products

• 114045-96-4 4-Benzyloxy-2-fluoro-benzoic Acid 
• 729590-55-0 C₁₈H₁₇FO₃ 
• 119776-15-7 2-fluoro-4-benzyloxyacetophenone 
• 239803-76-0 (R)-(-)-4-(1-methylheptyloxycarbonyl)-3-fluorophenyl 4'-[6-(3-methyloxetan-3-ylmethoxy)hexyloxy]biphenyl-4-carboxylate 
• 239803-78-2 4-(1-propylbutyloxycarbonyl)-3-fluorophenyl 4'-[6-(3-methyloxetan-3-ylmethoxy)hexyloxy]biphenyl-4-carboxylate 
• 356058-50-9 (S)-(+)-4-(2-methylbutyloxycarbonyl)-3-fluorophenyl 4'-[6-(3-methyloxetan-3-ylmethoxy)hexyloxy]biphenyl-4-carboxylate 
• 239803-48-6 (R)-(-)-1-methylheptyl 4-benzyloxy-2-fluorobenzoate 
• 356058-47-4 1-propylbutyl 4-benzyloxy-2-fluorobenzoate 
• 356058-46-3 (S)-(+)-2-methylbutyl 4-benzyloxy-2-fluorobenzoate 
• 114045-95-3 (R)-(-)-1-methylheptyl 4-hydroxy-2-fluorobenzoate 
• 356058-48-5 1-propylbutyl 4-hydroxy-2-fluorobenzoate 
• 106315-86-0 (S)-(+)-2-methylbutyl 4-hydroxy-2-fluorobenzoate 
• 121669-85-0 2-Fluoro-4-hydroxy-benzoic acid (S)-1-methyl-heptyl ester 
• 185836-35-5 2-fluoro-4-phenylmethoxybenzonitrile 

Relevant academic research and scientific papers

COMPOUNDS FOR TARGETED DEGRADATION OF BRD9

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide

The present invention provides a crystal of (6S,9aS)-N-benzyl-8-({6-[3-4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl} methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

List fluoro Radicamine compounds and their use and preparation method

The invention discloses a mono-fluorinated Radicamine compound which has a structure as shown in a formula (1), and further provides a preparation method for the mono-fluorinated Radicamine compound with the structure as shown in the formula (1) and an application of the mono-fluorinated Radicamine compound or the mono-fluorinated Radicamine compound prepared with the method to preparation of drugs for preventing and/or treating diabetes, drugs for preventing and/or treating Gaucher's diseases, drugs for preventing and/or treating tumors or antiviral drugs. The mono-fluorinated Radicamine compound provided by the invention is good in glycosidase inhibition activity.

Fluorinated Radicamine A and B: Synthesis and Glycosidase Inhibition

Fluorinated derivatives of radicamine A and radicamine B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies showed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom. C-7 or C-11 fluorination of the aromatic ring decreased α-glucosidase inhibition of the derivatives, whereas C-8 or C-10 fluorination preserved glycosidase inhibitory activities. Fluorinated derivatives of radicamine A and B have been synthesized from D-arabinose-derived cyclic nitrone. Structure-activity relationship studies revealed that glycosidase inhibition of these fluorinated derivatives was significantly influenced by the position of the fluorine atom.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Design, synthesis and evaluation of potent G-protein coupled receptor 40 agonists

GPR40 has emerged as an attractive drug target for the treatment of type 2 diabetes due to its role in the enhancement of insulin secretion with glucose dependency. With the aim to improve the metabolic and safety profiles, a series of novel phenylpropionic acid derivatives were synthesized. Extensive structural optimization led to identification of compounds 22g and 23e as potent GPR40 agonists with moderate liver microsomal stability. All the discovery supported further exploration surrounding this scaffold.

(6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound

A compound represented by formula (1) or pharmaceutically acceptable salt thereof: wherein R1 is a C1-6 alkyl group; R2 and R3 are the same or different from each other and each is a hydrogen atom or a C1-6 alkyl group; X2, X3 and X4 are the same or different from each other and each is a hydrogen atom or a halogen atom; and X5 is a hydrogen atom or —P(═O)(OH)2 has a Wnt Pathway modulating activity.

SUBSTITUTED ALKYL CARBOXYLIC ACID DERIVATIVES AS GPR AGONISTS

The present invention relates to substituted alkyl carboxylic acid derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as GPR (G-protein coupled receptor) agonists,

P-Hydroxyphenacyl photoremovable protecting groups Robust photochemistry despite substituent diversity

A broadly based investigation of the effects of a diverse array of substituents on the photochemical rearrangement of p-hydroxyphenacyl esters has demonstrated that common substituents such as F, MeO, CN, CO2R, CONH2, and CH3 have little effect on the rate and quantum efficiencies for the photo-Favorskii rearrangement and the release of the acid leaving group or on the lifetimes of the reactive triplet state. A decrease in the quantum yields across all substituents was observed for the release and rearrangement when the photolyses were carried out in buffered aqueous media at pHs that exceeded the ground-state pKa of the chromophore where the conjugate base is the predominant form. Otherwise, substituents have only a very modest effect on the photoreaction of these robust chromophores.